期刊文献+

肥厚型梗阻性心肌病的不合理用药分析 被引量:5

Inappropriate Drug Therapy for Hypertrophic Obstructive Cardiomyopathy
下载PDF
导出
摘要 目的:分析肥厚型梗阻性心肌病(HOCM)患者的药物治疗现状,促进临床合理用药。方法:观察303例门诊及住院HOCM患者β受体阻滞剂、钙通道阻滞剂(CCB)、血管紧张素转换酶抑制剂(ACEI)/血管紧张素Ⅱ受体阻滞剂(ARB)、利尿剂、洋地黄类、硝酸酯类等药物的使用分布情况,并分析其不合理用药。结果:①β受体阻滞剂与钙通道阻滞剂使用状况:单用β受体阻滞剂者91例(30.0%),单用钙通道阻滞剂者33例(10.9%),β受体阻滞剂合用钙通道阻滞剂者166例(54.8%),β受体阻滞剂或钙通道阻滞剂均未使用者13例(4.3%)。在199例使用钙通道阻滞剂的患者中,苯烷胺类钙通道阻滞剂(维拉帕米)占54例(27.1%),地尔硫类钙通道阻滞剂(硫氮酮)占106例(53.3%),二氢吡啶类钙通道阻滞剂(如硝苯地平)占39例(19.6%)。②其他药物使用状况:血管紧张素转换酶抑制剂及血管紧张素Ⅱ受体阻滞剂125例(41.3%),利尿剂70例(23.1%),洋地黄类17例(5.6%),硝酸酯类64例(21.1%),乙胺碘肤酮15例(5.0%)。不合理使用血管紧张素转换酶抑制剂及血管紧张素Ⅱ受体阻滞剂、利尿剂、洋地黄类或硝酸酯类药物合计102例(33.7%)。结论:肥厚型梗阻性心肌病的药物治疗以β受体阻滞剂、钙通道阻滞剂为主,但仍存在不规范用药。 Objective: To investigate the medical treatment of hypertrophic obstructive cardiomyopathy (HOCM). Methods: Three hundred and three patients of HOCM in Fu Wai hospital from January 1992 to December 2006 were studied. The prescriptions of adrenergic beta-antagonists, calcium channel blockers, angiotensin-converting enzyme inhibitors ( ACE inhibitors)/angiotensin Ⅱ receptor blockers (ARB) , diuretics, digoxin, nitrates were collected and evaluated. Results:①Ninety-one(30.0% ) patients were given single adrenergic beta-antagonists, 33 (10. 9% ) patients were given single calcium channel blockers,and 166 (54.8%) patients were given adrenergic beta-antagonists combined with calcium channel blockers. The other 13 (4. 3% ) were given neither adrenergic beta-antagonists nor calcium channel blockers. In 199 patients who received calcium channel blockers, 54 (27.1%) patients were given verapamil, 106 (53.3%) were given diltiazem, 39 ( 19.6% ) were given dihydropyridines. ②One hundred and twenty-five (41.3%) patients were given ACE inhibitors/ARB, 70 (23. 1% ) patients were given diuretics, 17 (5.6%) patients were given digoxin, 64 (21.1%) patients were given nitrates, 15 (5.0%) patients were given amiodarone. One hundred and two (33.7%) patients were inappropriately treated with ACE inhibitors/ARB diuretics, digoxin, or nitrates. Conclusion: The most popular agents of HOCM were still adrenergic beta-antagonists and calcium channel blockers, but sometimes ACE inhibitors/ARB, diuretics, digoxin or nitrates, were inappropriately prescribed.
出处 《中国循环杂志》 CSCD 北大核心 2007年第5期355-357,共3页 Chinese Circulation Journal
关键词 心肌病 肥厚性梗阻不合理用药 Cardiomyopathy,hypertrophic Obstructive Inappropriate drug therapy
  • 相关文献

参考文献10

  • 1Spirito P,Autore C.Management of hypertrophic cardiomyopathy.BMJ,2006,332:1251-1255.
  • 2Maron BJ,Towbin JA,Thiene G,et al.Contemporary definitions and classification of the cardiomyopathies:an American Heart Association Scientific Statement from the Council on Clinical Cardiology,Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention.Circulation,2006,113:1807-1816.
  • 3Maron BJ,Ackerman MJ,Nishimura RA,et al.Task Force 4:HCM and other cardiomyopathies,mitral valve prolapse,myocarditis,and Marfan syndrome.J Am Coll Cardiol,2005,45:1340-1345.
  • 4Semsarian C,CSANZ Cardiovascular Genetics Working Group.Guidelines for the diagnosis and management of hypertrophic cardiomyopathy.Heart Lung Circ,2007,16:16-18.
  • 5Maron BJ,McKenna WJ,Danielson GK,et al.American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy.Eur Heart J,2003,24:1965-1991.
  • 6杨宏,樊朝美.肥厚型梗阻性心肌病治疗中的合理用药[J].中国医刊,2005,40(5):54-56. 被引量:3
  • 7Roberts R,Sigwart U.Current Concepts of the Pathogenesis and Treatment of Hypertrophic Cardiomyopathy.Circulation,2005,112:293-296.
  • 8Mingo S,Benedicto A,Jimenez MC,et al.Dynamic left ventricular outflow tract obstruction secondary to catecholamine excess in a normal ventricle.Int J Cardiol,2006,112:393-396.
  • 9Sherrid MV.Pathophysiology and treatment of hypertrophic cardiomyopathy.Prog Cardiovasc Dis,2006,49:123-151.
  • 10Rydén L,Gadler F.Pharmacological therapy for hypertrophic cardiomyopathy:what is the evidence for success.Eur Heart J Supplements,2001,3:L21-L25.

二级参考文献15

  • 1Geisterfer-Lowrance AA, Kass S, Tanigawa G, et al. A molecular basis for familial hypertrophic cardiomyopathy: a beta cardiac myosin heavy chain gene missense mutation[J]. Cell, 1990, 62∶999- 1006.
  • 2Marian Aj, Roberts R. The molecular genetic basis for hypertrophic cardiomyopathy[J].J Mol Cell Cardiol,2001,33∶655-670.
  • 3Spirito P, Seidman CE, McKenna WJ,et al. The management of hypertrophic cardiomyopathy[J]. N Engl J Med,1997,336∶775-785.
  • 4Nishimura RA, Holmes DR. Hypertrophic Obstructive Cardiomyopathy[J]. N Engl J Med,2004,350∶1320-1327.
  • 5Cohen LS, Braunwald E. Amelioration of angina pectoris in idiopathic hypertrophic subaortic stenosis with beta-adrenergic blockade[J].Circulation, 1967,35∶847-851.
  • 6Rosing DR, Kent KM, Borer JS, et al. Verapamil therapy: a new approach to pharmacologyic treatment of hypertrophic cardiomyopathy hemodynamic effects[J].Circulation,1979,60∶1201-1207.
  • 7Wigle ED, Rakowski H, Kimball BP, et al.Hypertrophic cardiomyopathy: clinical spectrum and treatment[J].Circulation,1995, 92∶1680-1692.
  • 8Epstein SE, Rosing DR. Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy[J].Circulation ,1981,64∶437-441.
  • 9Richardson PJ.Calcium antagonists in cardiomyopathy[J]. Br J Clin Pract Symp, 1988,60 (Supp.)∶33.
  • 10Adelman AG, Wigle ED, Ranganathan N, et al.The clinical course subaortic stenosis. A retrospective and prospective study of 60 hemodynamically proved cases[J]. Ann Intern Med, 1972, 77∶515-525.

共引文献2

同被引文献19

  • 1姜腾勇,韩智红,吴学思,马长生,吕树铮,康俊萍,胡荣,贾长琪.肥厚型心肌病合并冠心病的诊断[J].中华心血管病杂志,2004,32(9):822-824. 被引量:16
  • 2李琳,鲁春燕.肥厚型梗阻性心肌病的药物治疗[J].实用心脑肺血管病杂志,2006,14(6):504-505. 被引量:2
  • 3高阅春,李宇,韩智红,张晓玲,赵华,姜腾勇.老年肥厚型梗阻性心肌病消融和起搏器治疗的对照观察[J].中华心血管病杂志,2007,35(4):333-336. 被引量:7
  • 4孙军燕,张兆琪,贺毅,姜腾勇,李宇,范占明,王永梅.肥厚性心肌病MR延迟增强与心肌钙蛋白Ⅰ相关性的初步研究[J].中华放射学杂志,2007,41(8):796-799. 被引量:3
  • 5Coats C J, Elliott PM. Current management of hypertrophic cardiomyopathy. Curt Treat Options Cardiovasc Med, 2008,10: 496 -504.
  • 6Pai RG, Varadarajan P. Prognostic implications of mitral regurgitation in patients with severe aortic regurgitation. Circulation,2010,122 ( 11 Suppl) :S43-S47.
  • 7Dearani JA, Ommen SR, Gersh B J, et al. Surgery insight : septal myectomy for obstructive hypertrophic cardiomyopathy-the Mayo Clinic experience. Nat Clin Pract Cardiovasc Med,2007,4:503 - 512.
  • 8Maron B J, Mckenna WJ, Danielsan GK, et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines. J Am Coil Cardiol, 2003,42 : 1687-1713.
  • 9Maron BJ. Sudden death in hypertrophic eardiomyopathy. J Cardiovasc Transl Res,2009 ,2 :368-380.
  • 102011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy. Circulation, 2011.

引证文献5

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部